























## References

- <sup>1</sup> Moderna (updated July 14, 2022) Moderna COVID-19 Vaccine, mRNA-1273 SARS-CoV-2 vaccine, Suspension for intramuscular injection: *Product Monograph* <https://covid-vaccine.canada.ca/info/pdf/covid-19-vaccine-moderna-pm-en.pdf>
- <sup>2</sup> National Advisory Committee on Immunization. (2021). Canadian Immunization Guide (Evergreen ed.). Ottawa, ON: Public Health Agency of Canada <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html>
- National Advisory Committee on Immunization. (2021 December 3). Rapid response: Updated recommendations on the use of authorized COVID-19 Vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines. [https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-recommendation-use-covid-19-vaccines-individuals-aged-12-years-older-myocarditis-pericarditis-reported-following-mrna-vaccines.pdf](https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-recommendation-use-covid-19-vaccines-individuals-aged-12-years-older-myocarditis-pericarditis-reported-following-mrna-vaccines/rapid-response-recommendation-use-covid-19-vaccines-individuals-aged-12-years-older-myocarditis-pericarditis-reported-following-mrna-vaccines.pdf)
- National Advisory Committee on Immunization. (2021 December 3). Guidance on booster COVID-19 vaccine doses in Canada – Update January 28, 2022. <https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-booster-covid-19-vaccine-doses.html>
- National Advisory Committee on Immunization. (2022 January 14). Re-vaccination with COVID-19 vaccine following myocarditis and/or pericarditis. <https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/summary-advice-vaccination-covid-19-vaccines-following-myocarditis-with-without-pericarditis.html>
- National Advisory Committee on Immunization. (2022 January 28). Rapid response: Guidance on the use of booster COVID-19 vaccine doses in adolescents 12-17 years of age. <https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/guidance-use-booster-covid-19-vaccines-adolescents-12-17-years-age.pdf>
- National Advisory Committee on Immunization. (2022 February 4) NACI rapid response: Updated guidance on COVID-19 vaccination timing for individuals previously infected with SARS-CoV-2. <https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-guidance-covid-19-vaccination-timing-individuals-previously-infected-sars-cov-2.html>
- National Advisory Committee on Immunization. (2022 April 5). Initial guidance on a second booster dose of COVID-19 vaccines in Canada. <https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/naci-guidance-second-booster-dose-covid-19-vaccines.pdf>
- National Advisory Committee on Immunization. (2022 October 7). Updated guidance on COVID-19 vaccine booster doses in Canada. <https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/guidance-covid-19-vaccine-booster-doses.pdf>
- National Advisory Committee on Immunization. (2022 September 9). Updated guidance on COVID-19 vaccines for individuals who are pregnant or breastfeeding. <https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/guidance-covid-19-vaccines-individuals-pregnant-breastfeeding.pdf>
- National Advisory Committee on Immunization. (2023 January 20). Guidance on COVID-19 vaccine booster doses: initial considerations for 2023. <https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/guidance-covid-19-vaccine-booster-doses-initial-considerations-2023.pdf>
- <sup>3</sup> Health Canada. Recalls and safety alerts. (2020 December 12) Pfizer-BioNTech COVID-19 vaccine: Health Canada recommendations for people with serious allergies. <https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/74543a-eng.php>
- <sup>4</sup> Shimabukuro, T., Kim, S., et al. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. *The New England Journal of Medicine*. (2021 April 21) <https://www.nejm.org/doi/full/10.1056/NEJMoa2104983>
- <sup>5</sup> Centers for Disease Control and Prevention. (updated 2022 July 14) Information about COVID-19 Vaccines for People who are Pregnant or Breastfeeding. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html>
- <sup>6</sup> Centers for Disease Control and Prevention. (2021, September). Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>
- <sup>7</sup> Benschop, et al. (2021 December 16). The effect of anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, on endogenous immune response to COVID-19 vaccination. <https://doi.org/10.1101/2021.12.15.21267605>